Molecular Templates, Inc.
MTEM
|
$1.55
3.54%
15K
|
Health Technology
(0.0% 1d) (-28.4% 1m) (314.5% 1y) (0.0% 2d) (5.8% 3d) (11.6% 7d) (-37.43% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 8,330,115
http://www.mtem.com
Sec Filling | Patents | 168 employees
(US) Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. Molecular Templates was founded by Eric E. Poma, Jean Gariépy and Leigh Revers on October 17, 2001 and is headquartered in Austin, TX.
cancer treatment
add to watch list Paper trade email alert is off
Press-releases
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for molecular study
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 13:30) - biospace.com/
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for meeting molecular study
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Published: 2024-03-29 (Crawled : 12:30) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
| Email alert
Add to watchlist
business update financial results molecular
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 18.3%
H: 0.0%
C: -19.42%
million offering agreement molecular
Molecular Templates, Inc. Provides Interim Update
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 11.96%
H: 0.0%
C: -6.55%
update molecular
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-08 (Crawled : 23:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: -1.13%
conference life sciences molecular
Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $52.795 -3.02% -3.12% 300K
|
|
| O: 0.2%
H: 5.99%
C: 5.65%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -2.94%
H: 3.03%
C: 3.03%
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -0.6%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.66%
H: 0.64%
C: -1.11%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 1.1%
H: 0.27%
C: -1.64%
companies growth market
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -3.75%
H: 5.16%
C: 1.3%
business update financial results molecular
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 8.15%
H: 1.13%
C: -5.65%
mt-8421 tumors trial molecular
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
VTVT | $25.39 1.66% 1.63% 4.2K
|
Health Technology
|
| O: -0.02%
H: 2.44%
C: -2.37%
OMER | $3.04 -1.62% -1.64% 250K
|
Health Technology
|
| O: 1.77%
H: 6.96%
C: 6.09%
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 3.5%
H: 0.0%
C: -5.12%
medical therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10